# A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

> **NCT07659795** · PHASE2 · RECRUITING · sponsor: **Verastem, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** VS-7375
- **DRUG:** cetuximab
- **DRUG:** panitumumab
- **DRUG:** Cetuximab + mFOLFOX6

## Key facts

- **NCT ID:** NCT07659795
- **Lead sponsor:** Verastem, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-28
- **Primary completion:** 2027-06
- **Final completion:** 2028-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07659795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07659795, "A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07659795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*